Limits...
Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years.

Yan W, Chen J, Zhou Y, Zhou Z, Mai Z, Ji Z, Li H, Zhang F - Springerplus (2014)

Bottom Line: The overall survival rate was 90%, and the cancer-specific survival rate was 97%.The bNED rates in the low-risk, intermediate-risk and high-risk groups were 86%, 79% and 64%, respectively (P = 0.040).The patients with PSA <20 ng/ml, a positive biopsy rate lower than 0.5, and D90 ≥ 140 Gy had lower biochemical recurrence (P = 0.028, 0.006, 0.009, respectively).

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China.

ABSTRACT

Purpose: To investigate the long-term efficacy of (125)I brachytherapy in early-stage prostate cancer and to identify correlating factors.

Methods: This study included 117 cases of early stage prostate cancer. The patients ranged in age from 51 to 84 years, with a mean of 73 years. The features of the study population were as follows: the PSA ranged from 0.4 to 47.6 ng/ml (median, 14.7); the Gleason score ranged from 4 to 9 (mean, 6.4); the clinical stage ranged from T1b to T2c; and the positive biopsy rate ranged from 0.08 to 1.0 (mean, 0.45). The mean D90 was 142 Gy and ranged from 106 Gy to 170 Gy. The numbers of low-risk, intermediate-risk and high-risk prostate cancer cases were 22, 29 and 66, respectively. The biochemical no evidence of disease (bNED) rate and overall survival were recorded. Factors that correlated with the outcomes were evaluated.

Results: With a mean follow up of 84 months, 33 cases had biochemical recurrence, with a bNED rate of 72%. The overall survival rate was 90%, and the cancer-specific survival rate was 97%. The bNED rates in the low-risk, intermediate-risk and high-risk groups were 86%, 79% and 64%, respectively (P = 0.040). The patients with PSA <20 ng/ml, a positive biopsy rate lower than 0.5, and D90 ≥ 140 Gy had lower biochemical recurrence (P = 0.028, 0.006, 0.009, respectively).

Conclusions: The long-term efficacy of (125)I brachytherapy in early stage prostate cancer was shown. bNED is related to risk stratification, PSA level, positive biopsy rate and D90.

No MeSH data available.


Related in: MedlinePlus

Patients whose D90 ≥ 140 Gy had better biochemical control than those D90 < 140 Gy (P = 0.009).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4117862&req=5

Fig5: Patients whose D90 ≥ 140 Gy had better biochemical control than those D90 < 140 Gy (P = 0.009).

Mentions: bNED was also examined among the different subgroups (Table 3). Patients whose PPC was lower than 50% had a lower biochemical recurrence likelihood than those whose PPC was higher than 50% (P = 0.006) (Figure 4). Patients who received a D90 higher than 140 Gy had better biochemical control than those who received a D90 lower than 140 Gy (P = 0.009) (Figure 5). Patients with a PSA level lower than 20 ng/ml had a lower biochemical recurrence rate than those with a PSA level higher than 20 ng/ml (P = 0.028). The bNED rate did not significantly differ between clinical stage T1b-T2b and T2c (P = 0.094). Additionally, no significant differences in biochemical relapse were observed in the subgroups with a Gleason score higher or lower than 7 or the subgroups with a prostate volume larger or smaller than 30 ml (P = 0.137, 0.104).Table 3


Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years.

Yan W, Chen J, Zhou Y, Zhou Z, Mai Z, Ji Z, Li H, Zhang F - Springerplus (2014)

Patients whose D90 ≥ 140 Gy had better biochemical control than those D90 < 140 Gy (P = 0.009).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4117862&req=5

Fig5: Patients whose D90 ≥ 140 Gy had better biochemical control than those D90 < 140 Gy (P = 0.009).
Mentions: bNED was also examined among the different subgroups (Table 3). Patients whose PPC was lower than 50% had a lower biochemical recurrence likelihood than those whose PPC was higher than 50% (P = 0.006) (Figure 4). Patients who received a D90 higher than 140 Gy had better biochemical control than those who received a D90 lower than 140 Gy (P = 0.009) (Figure 5). Patients with a PSA level lower than 20 ng/ml had a lower biochemical recurrence rate than those with a PSA level higher than 20 ng/ml (P = 0.028). The bNED rate did not significantly differ between clinical stage T1b-T2b and T2c (P = 0.094). Additionally, no significant differences in biochemical relapse were observed in the subgroups with a Gleason score higher or lower than 7 or the subgroups with a prostate volume larger or smaller than 30 ml (P = 0.137, 0.104).Table 3

Bottom Line: The overall survival rate was 90%, and the cancer-specific survival rate was 97%.The bNED rates in the low-risk, intermediate-risk and high-risk groups were 86%, 79% and 64%, respectively (P = 0.040).The patients with PSA <20 ng/ml, a positive biopsy rate lower than 0.5, and D90 ≥ 140 Gy had lower biochemical recurrence (P = 0.028, 0.006, 0.009, respectively).

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China.

ABSTRACT

Purpose: To investigate the long-term efficacy of (125)I brachytherapy in early-stage prostate cancer and to identify correlating factors.

Methods: This study included 117 cases of early stage prostate cancer. The patients ranged in age from 51 to 84 years, with a mean of 73 years. The features of the study population were as follows: the PSA ranged from 0.4 to 47.6 ng/ml (median, 14.7); the Gleason score ranged from 4 to 9 (mean, 6.4); the clinical stage ranged from T1b to T2c; and the positive biopsy rate ranged from 0.08 to 1.0 (mean, 0.45). The mean D90 was 142 Gy and ranged from 106 Gy to 170 Gy. The numbers of low-risk, intermediate-risk and high-risk prostate cancer cases were 22, 29 and 66, respectively. The biochemical no evidence of disease (bNED) rate and overall survival were recorded. Factors that correlated with the outcomes were evaluated.

Results: With a mean follow up of 84 months, 33 cases had biochemical recurrence, with a bNED rate of 72%. The overall survival rate was 90%, and the cancer-specific survival rate was 97%. The bNED rates in the low-risk, intermediate-risk and high-risk groups were 86%, 79% and 64%, respectively (P = 0.040). The patients with PSA <20 ng/ml, a positive biopsy rate lower than 0.5, and D90 ≥ 140 Gy had lower biochemical recurrence (P = 0.028, 0.006, 0.009, respectively).

Conclusions: The long-term efficacy of (125)I brachytherapy in early stage prostate cancer was shown. bNED is related to risk stratification, PSA level, positive biopsy rate and D90.

No MeSH data available.


Related in: MedlinePlus